JDM patients who test positive for anti-nuclear matrix protein 2 (anti-NXP2) often exhibit more severe clinical manifestations, including gastrointestinal (GI) involvement, calcinosis, edema, skin ulcers, and a poorer prognosis (2, 3). This evidence concerns the gene MORC3 and juvenile dermatomyositis.